Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

What is the cost of humira per month?

See the DrugPatentWatch profile for humira

What does Humira cost per month in the US?

Humira (adalimumab) pricing varies a lot by country, insurance plan, and whether you’re paying cash or using manufacturer or pharmacy assistance. Because the provided information does not include any specific price list, I can’t give an accurate “per month” dollar figure.

How is a “per month” price usually calculated for Humira?

A common way to estimate monthly cost is to start from the per-dose list price (or the pharmacy’s price for your plan) and divide by the dosing interval. Humira is commonly prescribed every week or every other week depending on the condition, so your monthly amount can differ even if the per-dose price is the same.

What information do you need to give you an exact monthly cost?

If you share:
- your country (and ZIP/postal code if US),
- your dose schedule (weekly vs every other week, or the exact mg),
- whether you have insurance (and if you know your plan type),
- whether you want list price, cash price, or your expected out-of-pocket cost,

…I can help you translate that into a monthly estimate based on the pricing context you’re using.

What are typical reasons monthly costs differ?

Even with the same prescribed dose, monthly costs can change due to:
- negotiated insurance discounts vs list (wholesale acquisition cost),
- copay amounts and deductibles,
- patient assistance programs and pharmacy discounts,
- product form and strength (pen vs syringe, different mg).

If you want, I can estimate it with your details

Tell me your location (country + state/ZIP), how often you take Humira, and whether you’re paying cash or through insurance, and I’ll calculate an estimated monthly cost range for your situation.



Other Questions About Humira :

humira patent cliff Humira crohn's disease? Humira biologic company overview? Humira injections cost? What are common side effects of using humira biosimilars? Humira long term side effects? Can specific conditions influence humira biosimilars side effect profiles?

AI-Drug Label Prescribing Information Alignment Report

96
96%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

All evaluated claims under the requested warning topic (serious infections and malignancy) are supported by the provided HUMIRA label excerpts (Sections 5.1 and 5.2), with no detected contradictions or unsupported additions within the supplied claim set.


Category Scores

Warnings
100
Excellent

Accurate Statements

HUMIRA increases the risk of serious infections, which may lead to hospitalization or death, and opportunistic infections have been reported.
Supported by Section 5.1 Serious Infections (increased risk of serious infections; opportunistic infections reported).
HUMIRA should not be initiated in patients with an active infection, including localized infections.
Supported by Section 5.1 Serious Infections (do not initiate in patients with active infection including localized).
HUMIRA should be discontinued if a patient develops a serious infection or sepsis.
Supported by Section 5.1 Serious Infections (discontinue if serious infection or sepsis develops).
Patients 65 years of age and older, those with co-morbid conditions, and those taking concomitant immunosuppressants may be at greater risk of infection.
Supported by Section 5.1 Serious Infections (greater risk in these groups).
TNF blockers including HUMIRA are associated with malignancies, including lymphoma and other malignancies (some fatal), reported in children and adolescent patients.
Supported by Section 5.2 Malignancies (lymphoma and other malignancies including fatalities in children/adolescents).
Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL) have been reported with TNF blockers including HUMIRA, with an aggressive and often fatal course.
Supported by Section 5.2 Malignancies (HSTCL described as rare, aggressive, often fatal; post-marketing cases).

Unsupported Statements


Contradictions


Important Omissions

The evaluation did not explicitly include the label text elements about (a) detailed list of opportunistic organisms, (b) guidance to close monitor for infection including possible TB development during and after treatment, and (c) latent TB testing prior to and during therapy (all present in Section 5.1).
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
Within the provided claim set, all statements about serious infections and malignancy risk are label-supported and no contradictions were identified. A few label monitoring/testing details present in the excerpts were not included in the evaluated claims, but they were not asserted incorrectly.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Omitted label monitoring and latent TB testing instructions that are part of the Serious Infections warning excerpt.

Suggested Improvement
Include the label-supported statements regarding close monitoring for infection (including TB) during and after treatment and latent TB testing prior to and during therapy when discussing the Serious Infections warning.